Sanpower Reconstructs Dendreon Deal To Drive Better Growth

Sanpower Group is planning the first Asian launch of Provenge in Hong Kong after acquiring a local cell therapy manufacturing facility, amid the ongoing sale of Dendreon to its public holding company Nanjing Cenbest, the latest deal in the surge of traditional companies breaking into the healthcare sector in China.

Coins

Five months after completing the acquisition of Dendreon Corp., Chinese conglomerate Sanpower Group has taken a substantial step toward making real progress with the heart of the deal, Provenge (sipuleucel-T), as it is preparing to file the drug registration with the Pharmacy and Poisons Board of Hong Kong, the first move to advance the immunotherapy’s development in Asia.

Through a Hong Kong entity, Dendreon HK Limited, Sanpower finished the acquisition of a manufacturing facility in Wong Chuk Hang...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia